S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Liberty Biopharma Stock Forecast, Price & News

+2.00 (+∞)
(As of 10/10/2018)
Today's Range
Now: C$2.00
50-Day Range
MA: C$2.00
52-Week Range
Now: C$2.00
Volume700 shs
Average Volume23,286 shs
Market CapitalizationC$21.54 million
P/E RatioN/A
Dividend YieldN/A
Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.


Overall MarketRank

0.58 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC$0.79 per share



Market CapC$21.54 million
Next Earnings DateN/A
OptionableNot Optionable
+2.00 (+∞)
(As of 10/10/2018)
30 days | 90 days | 365 days | Advanced Chart

Receive LTY News and Ratings via Email

Sign-up to receive the latest news and ratings for LTY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Liberty Biopharma (CVE:LTY) Frequently Asked Questions

What stocks does MarketBeat like better than Liberty Biopharma?

Wall Street analysts have given Liberty Biopharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Liberty Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Liberty Biopharma's key competitors?

What other stocks do shareholders of Liberty Biopharma own?

Who are Liberty Biopharma's key executives?

Liberty Biopharma's management team includes the following people:
  • Mr. Norman Tsui, Pres, CEO & Director (Age 45)
  • Mr. Shui Yan Tam, Chief Financial Officer (Age 44)
  • Dr. Michael T. McNamara, Medical Advisor & Director
  • Dr. Richard Huang Ph.D., Chief Technology Officer (Age 42)
  • Dr. Richard Cook M.D., Msc., FRCSC, Chief Medical Officer

What is Liberty Biopharma's stock symbol?

Liberty Biopharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LTY."

How do I buy shares of Liberty Biopharma?

Shares of LTY and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What is Liberty Biopharma's stock price today?

One share of LTY stock can currently be purchased for approximately C$2.00.

How big of a company is Liberty Biopharma?

Liberty Biopharma has a market capitalization of C$21.54 million.

What is Liberty Biopharma's official website?

The official website for Liberty Biopharma is www.libertybiopharma.com.

How can I contact Liberty Biopharma?

Liberty Biopharma's mailing address is 2270-8788 McKim Way, RICHMOND, BC V6X 4E2, Canada. The biotechnology company can be reached via phone at +1-604-3777575.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.